^
    Back
    Association details:
    Biomarker:ER mutation
    Cancer:Breast Cancer
    Drug:fulvestrant (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

    Excerpt:
    ...- Activating ESR1 mutation (e.g....
    Trial ID:
    NCT04256941
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

    Excerpt:
    ...The blood sample is clarified to be ESR1 mutated,...
    Trial ID:
    NCT03202862
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res Treat
    Title:

    ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling

    Excerpt:
    The selective estrogen receptor degrader, fulvestrant, significantly reduced the anchorage-independent growth of ESR1 mutant-expressing cells, while combination treatments with the mTOR inhibitor everolimus, or an inhibitor blocking IGF1R, and the insulin receptor significantly enhanced anti-proliferative responses.
    DOI:
    10.1007/s10549-017-4250-4